| 1 | 1 | | I |
|---|
| 2 | 2 | | 119THCONGRESS |
|---|
| 3 | 3 | | 1 |
|---|
| 4 | 4 | | STSESSION H. R. 1672 |
|---|
| 5 | 5 | | To amend title XI of the Social Security Act to protect access to genetically |
|---|
| 6 | 6 | | targeted technologies. |
|---|
| 7 | 7 | | IN THE HOUSE OF REPRESENTATIVES |
|---|
| 8 | 8 | | FEBRUARY27, 2025 |
|---|
| 9 | 9 | | Mr. D |
|---|
| 10 | 10 | | AVISof North Carolina (for himself, Mr. JOYCEof Pennsylvania, Mr. |
|---|
| 11 | 11 | | G |
|---|
| 12 | 12 | | OTTHEIMER, Ms. TENNEY, Mr. YAKYM, Mr. MORELLE, Mr. HUDSON, |
|---|
| 13 | 13 | | Mr. B |
|---|
| 14 | 14 | | EANof Florida, Mrs. MILLER-MEEKS, Mr. ALLEN, Ms. VAN |
|---|
| 15 | 15 | | D |
|---|
| 16 | 16 | | UYNE, Mr. PETERS, Mr. MOOREof Utah, and Mr. CRENSHAW) intro- |
|---|
| 17 | 17 | | duced the following bill; which was referred to the Committee on Energy |
|---|
| 18 | 18 | | and Commerce, and in addition to the Committee on Ways and Means, |
|---|
| 19 | 19 | | for a period to be subsequently determined by the Speaker, in each case |
|---|
| 20 | 20 | | for consideration of such provisions as fall within the jurisdiction of the |
|---|
| 21 | 21 | | committee concerned |
|---|
| 22 | 22 | | A BILL |
|---|
| 23 | 23 | | To amend title XI of the Social Security Act to protect |
|---|
| 24 | 24 | | access to genetically targeted technologies. |
|---|
| 25 | 25 | | Be it enacted by the Senate and House of Representa-1 |
|---|
| 26 | 26 | | tives of the United States of America in Congress assembled, 2 |
|---|
| 27 | 27 | | SECTION 1. SHORT TITLE. 3 |
|---|
| 28 | 28 | | This Act may be cited as the ‘‘Maintaining Invest-4 |
|---|
| 29 | 29 | | ments in New Innovation Act’’. 5 |
|---|
| 30 | 30 | | VerDate Sep 11 2014 01:44 Mar 15, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1672.IH H1672 |
|---|
| 31 | 31 | | kjohnson on DSK7ZCZBW3PROD with $$_JOB 2 |
|---|
| 32 | 32 | | •HR 1672 IH |
|---|
| 33 | 33 | | SEC. 2. AMENDMENT TO DEFINITION OF QUALIFYING SIN-1 |
|---|
| 34 | 34 | | GLE SOURCE DRUG. 2 |
|---|
| 35 | 35 | | Section 1192(e) of the Social Security Act (42 U.S.C. 3 |
|---|
| 36 | 36 | | 1320f–1(e)) is amended— 4 |
|---|
| 37 | 37 | | (1) in paragraph (1)(A)(ii), by inserting ‘‘(or, 5 |
|---|
| 38 | 38 | | in the case of an advanced drug product (as defined 6 |
|---|
| 39 | 39 | | in paragraph (4)), 11 years)’’ after ‘‘7 years’’; and 7 |
|---|
| 40 | 40 | | (2) by adding at the end the following new 8 |
|---|
| 41 | 41 | | paragraph: 9 |
|---|
| 42 | 42 | | ‘‘(4) A |
|---|
| 43 | 43 | | DVANCED DRUG PRODUCT DEFINED .— 10 |
|---|
| 44 | 44 | | For purposes of paragraph (1)(A)(ii), the term ‘ad-11 |
|---|
| 45 | 45 | | vanced drug product’ means a drug that incor-12 |
|---|
| 46 | 46 | | porates or utilizes a genetically targeted technology 13 |
|---|
| 47 | 47 | | (as defined in section 529A(c)(2) of the Federal 14 |
|---|
| 48 | 48 | | Food, Drug, and Cosmetic Act) that may result in 15 |
|---|
| 49 | 49 | | the modulation (including suppression, up-regula-16 |
|---|
| 50 | 50 | | tion, or activation) of the function of a gene or its 17 |
|---|
| 51 | 51 | | associated gene product.’’. 18 |
|---|
| 52 | 52 | | Æ |
|---|
| 53 | 53 | | VerDate Sep 11 2014 01:44 Mar 15, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6301 E:\BILLS\H1672.IH H1672 |
|---|
| 54 | 54 | | kjohnson on DSK7ZCZBW3PROD with $$_JOB |
|---|